Log in to your Inderes Free account to see all free content on this page.
ArcticZymes Technologies
Less than 1K followers
AZT
Oslo Børs
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
ArcticZymes Technologies is active in biotechnology. The company specializes in research and development of drugs for the treatment of autoimmune diseases. The main focus is on the development of glucans, the production of immunostimulants, and the analysis of enzymes. The vision is to test and develop the medicine and then further use it for RNA and DNA processes. The company was previously known as Biotec Pharmacon and is headquartered in Tromsø.
Read moreMarket cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
12.2.
2026
Annual report '25
7.5.
2026
Interim report Q1'26
28.5.
2026
General meeting '26
All
Press releases
ShowingAll content types
ArcticZymes Technologies Completes Share Buyback to Support Employee Share Purchase Program
AZT: ArcticZymes Technologies to present at DNB Carnegie Nordic Healthcare Conference
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio